End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
46.9 CNY | +2.00% | +6.52% | -27.26% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With a 2024 P/E ratio at 26.2 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.26% | 622M | - | ||
+17.63% | 83.4B | C+ | ||
-0.07% | 27.04B | C+ | ||
-11.48% | 16.96B | B | ||
-0.29% | 16.86B | A- | ||
+2.89% | 15.76B | A- | ||
+1.25% | 12.76B | B- | ||
+73.23% | 13.33B | C- | ||
+72.58% | 12.74B | C+ | ||
+1.77% | 12.32B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301333 Stock
- Ratings R&G PharmaStudies Co., Ltd.